The Department of Pharmaceuticals issued a corrigendum revising the minimum cumulative investment schedule for Group C (MSME) participants under the Production Linked Incentive (PLI) Scheme for Pharmaceuticals. The amendment provides beneficiaries with an additional year to meet the prescribed investment milestones while retaining the existing sales-growth eligibility criteria and other scheme provisions.
The Department of Pharmaceuticals has amended Appendix B of the operational guidelines for Group C (MSME) applicants under the PLI Scheme for Pharmaceuticals. The corrigendum revises the minimum cumulative investment schedule, extending the timeline for beneficiaries to achieve the required investment milestones.
Key points include:
- The minimum cumulative investment requirement is 20% by FY 2022 to 23, 40% by FY 2023 to 24, 60% by FY 2024 to 25, 80% by FY 2025 to 26 and 100% by FY 2026 to 27.
- Eligible applicants must submit fresh incentive claims for previous performance years, which will be examined under the applicable scheme guidelines and procedures.
- Existing year-on-year sales-growth eligibility criteria remain unchanged.
- Performance years for calculating incremental sales and incentive disbursement remain FY 2022 to 23 to FY 2027 to 28.
- All other provisions of the operational guidelines and subsequent amendments remain unchanged.
